

# Mark T Drayson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3127404/mark-t-drayson-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11  
papers

195  
citations

8  
h-index

11  
g-index

11  
ext. papers

275  
ext. citations

5.9  
avg, IF

2.11  
L-index

#	Paper	IF	Citations
11	Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. <i>Leukemia</i> , <b>2021</b> , 35, 2043-2053	10.7	10
10	Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 114	7	1
9	Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. <i>Health Technology Assessment</i> , <b>2019</b> , 23, 1-94	4.4	2
8	Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. <i>BMC Nephrology</i> , <b>2018</b> , 19, 178	2.7	14
7	Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. <i>Leukemia</i> , <b>2018</b> , 32, 1727-1738	10.7	27
6	Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 220-230	4.5	20
5	Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test. <i>BMC Nephrology</i> , <b>2017</b> , 18, 247	2.7	9
4	Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. <i>Lancet Haematology</i> , <b>2017</b> , 4, e584-e594	14.6	3
3	Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497). <i>British Journal of Haematology</i> , <b>2014</b> , 164, 888-90	4.5	11
2	Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e56422	3.7	32
1	Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. <i>Blood</i> , <b>2006</b> , 108, 2013-9	2.2	66